Chaofeng Huang

Chaofeng Huang has worked for a number of companies since 2008. Chaofeng began as a Visiting Scholar at Justus Liebig University Giessen in 2008, followed by Post-doctoral Associate positions at the University of Pittsburgh and Mallinckrodt Institute, Washington University in St Louis in 2009 and 2010, respectively. In 2013, they worked as a Radiochemist for both Avid Radiopharmaceuticals and Eli Lilly and Company. From 2015 to 2021, they were a Senior Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson, and is currently a Senior Director at Full-Life Technologies, where they focus on Targeted Radiopharmaceutical Therapy by using alpha, beta emitting radionuclides to fulfill unmet need in oncology.

Chaofeng Huang received a Bachelor's degree in Applied Chemistry from Tongji University in 2001. Chaofeng then earned a Master's degree in Medicinal and Pharmaceutical Chemistry from the Shanghai Institute of Pharmaceutical Industry in 2004. Finally, they completed a Doctor of Philosophy (Ph.D.) in Organic Chemistry from the University of Missouri-Columbia in 2009.